FDA Modernization Act 3.0: What It Means for Drug Testing in 2025
Key Takeaways
- The FDA Modernization Act removes the 1938 federal mandate requiring animal testing before human clinical trials
- Drug sponsors can now use NAMs (organ-on-chip, organoids, computational models) as primary preclinical evidence
- The law does not ban animal testing; it eliminates the legal requirement
- Major pharma companies including Roche, Pfizer, and Johnson & Johnson have expanded NAMs programs since passage
- The FDA has qualified multiple organ-on-chip platforms under its Innovative Science and Technology Approaches for New Drugs (ISTAND) program
The End of Mandatory Animal Testing
For 86 years, a single clause in the Federal Food, Drug, and Cosmetic Act of 1938 dictated the path every new drug had to follow: test on animals first, then test on humans. That clause is no longer in effect.
The FDA Modernization Act 2.0, signed into law on December 29, 2022, replaced the word "animal" in the original statute with "nonclinical tests or studies," opening the door to alternative methods. The subsequent FDA Modernization Act 3.0 expanded this framework with specific provisions for new approach methodologies (NAMs) and defined regulatory pathways for their adoption.
This is the most significant change in preclinical drug testing regulation since the original 1938 law was enacted in response to the sulfanilamide disaster that killed 107 people.
What the Original Law Required
Section 505(i) of the Federal Food, Drug, and Cosmetic Act specifically required "adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use" with the understanding that these tests were conducted in animals. For decades, this meant:
- Acute toxicity studies in at least two mammalian species (typically rodents and non-rodents)
- Repeat-dose toxicity studies lasting 14 to 90 days, depending on the intended human exposure duration
- Reproductive toxicity studies assessing effects on fertility, embryonic development, and postnatal growth
- Carcinogenicity studies in rodents for drugs intended for long-term use (typically 2-year studies)
- Genotoxicity assays including in vitro and in vivo tests for mutagenic potential
These requirements remain available as options, but they are no longer the sole acceptable pathway to an Investigational New Drug (IND) application.
Timeline: From 1938 to 2025
Enacted after the sulfanilamide disaster. Established the requirement for preclinical safety testing, interpreted as requiring animal testing for all new drugs.
The FDA acknowledged that the current drug development model was inefficient, with 92% of drugs that pass animal testing failing in human clinical trials.
Emulate Inc. submitted the first organ-on-chip data to the FDA as part of drug safety evaluation. The FDA accepted the data as supplementary evidence.
President Biden signed the act on December 29, 2022, as part of the Consolidated Appropriations Act. The word "animal" was replaced with "nonclinical tests or studies."
Additional legislation strengthened the framework with specific NAMs qualification pathways, funding provisions, and mandated FDA reporting on NAMs adoption metrics.
Multiple drug sponsors submitted IND applications using organ-on-chip and computational models as primary preclinical evidence, with animal data as supplementary rather than foundational.
What Changed: Section by Section
Section 505(i) Amendment
The original language requiring "tests by all methods reasonably applicable" with the assumption of animal testing was replaced with language explicitly permitting "nonclinical tests or studies, including in vitro, in silico, in chemico tests, or studies carried out with human biology-based test methods."
NAMs Qualification Framework
The FDA Modernization Act 3.0 established a formal qualification process for new approach methodologies. Drug sponsors can now submit context-of-use documentation for NAMs platforms, and once qualified, these platforms can be used across multiple drug programs without re-qualification.
Reporting Requirements
The FDA is now required to publish annual reports on the number of IND applications that include NAMs data, the types of NAMs used, and the outcomes of review decisions involving NAMs evidence.
Which NAMs Qualify Under the New Framework?
The legislation defines "nonclinical tests or studies" broadly to include:
- Organ-on-chip devices: Microfluidic systems with living human cells that replicate organ-level physiology. Lung-on-chip, liver-on-chip, and kidney-on-chip systems are the most advanced.
- Organoid models: 3D self-organizing cellular structures derived from stem cells that mimic organ architecture. Patient-derived tumor organoids are already used in oncology drug screening.
- In silico models: Computational and mathematical models that predict drug behavior, including pharmacokinetic (PK) modeling, quantitative systems pharmacology (QSP), and digital twin approaches.
- Bioprinted tissues: 3D-printed tissue constructs using living cells that replicate tissue-level structure and function.
- Multi-organ systems: Connected organ-on-chip platforms (body-on-chip) that model systemic drug distribution and inter-organ communication.
How Pharma Companies Are Responding
The pharmaceutical industry's response has been rapid. Within the first year following the Modernization Act 2.0:
- Roche established a dedicated NAMs division and published validation data comparing liver-on-chip toxicity predictions against clinical outcomes
- Johnson & Johnson expanded its partnership with Emulate Inc. to deploy lung-on-chip and intestine-on-chip systems across multiple therapeutic programs
- Pfizer integrated organ-on-chip data into three IND submissions for inflammation and fibrosis drug candidates
- Sanofi partnered with Mimetas to use OrganoPlate systems for kidney toxicity screening at scale
- AstraZeneca published data showing their in silico toxicity prediction models matched or exceeded animal study predictiveness for hepatotoxicity endpoints
The 92% Failure Rate Problem
One of the primary arguments supporting the Modernization Act is the long-documented failure rate of the animal-first model. According to FDA data:
- Over 90% of drugs that pass animal safety testing fail in human clinical trials
- The average cost to develop a single FDA-approved drug exceeds $2.6 billion
- The average timeline from discovery to approval is 12-15 years
- Approximately 30% of drugs fail in clinical trials specifically due to human toxicity that was not predicted by animal models
The species differences between animals and humans mean that animal testing is not just ethically questionable but scientifically limited. Human-relevant models offer the potential for better predictions of both safety and efficacy.
What This Does NOT Mean
Several misconceptions have emerged since the legislation's passage. It is important to clarify:
- Animal testing is not banned. Companies can still conduct animal studies if they choose. The law removes the mandate, not the option.
- NAMs are not automatically accepted. The FDA still reviews each submission individually. NAMs data must meet the same evidentiary standards as any preclinical data.
- This does not apply retroactively. Drugs currently in the pipeline under animal-tested INDs do not need to be re-evaluated.
- International requirements differ. The EMA, PMDA (Japan), and other regulators have their own frameworks. Drug companies seeking global approval may still need to satisfy country-specific animal testing requirements.
What Happens Next
The FDA Modernization Act sets the legal framework, but implementation is an ongoing process. Key developments to watch:
- The FDA's ISTAND program continues to qualify additional NAMs platforms, with multi-organ systems expected to receive qualification in 2025-2026
- The National Center for Advancing Translational Sciences (NCATS) is funding validation studies comparing NAMs predictions against clinical outcomes
- International harmonization efforts through the OECD and ICH are developing mutual recognition frameworks for NAMs data
- The EPA's NAMS adoption under TSCA continues to build the evidence base for regulatory acceptance of non-animal methods
Explore the Full Regulatory Landscape
Patient Analog provides comprehensive coverage of FDA, EMA, and international regulatory frameworks for new approach methodologies.
View Regulatory Hub Detailed Act Analysis